Zobrazeno 1 - 10
of 10 541
pro vyhledávání: '"Reporting System"'
Autor:
Permatasari, Paulina, Budiarso, Adi, Dartanto, Teguh, Samosir, Agunan Paulus, Saputro, Bramantya, Ekayana, Dewa, Agustono, Efid Dwi, Alim, Tri Emil, Hartono, Leni, Wahyuputri, Firli Wulansari, Wardhana, Irwanda Wisnu
Publikováno v:
Transforming Government: People, Process and Policy, 2024, Vol. 18, Issue 4, pp. 512-528.
Externí odkaz:
http://www.emeraldinsight.com/doi/10.1108/TG-07-2023-0098
Autor:
Wen-Hui Liu, Hui-Min Hu, Chen Li, Qing Shi, Chun-Hua Liu, An-Xiang Liu, Yi-Fan Li, Yi Zhang, Peng Mao, Bi-Fa Fan
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Triptans selectively agoniste 5-Hydroxytryptamine(5-HT) receptors and are widely used in the treatment of migraine. Nevertheless, there is a dearth of comprehensive real-world clinical research on the safety of triptans. In light
Externí odkaz:
https://doaj.org/article/65851d866a4644209009a8dfc2df51ad
Publikováno v:
Endocrine Connections, Vol 13, Iss 12, Pp 1-10 (2024)
Aim: Incretin therapies, including dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are crucial for type 2 diabetes treatment. Evidence of their association with gallbladder, biliary diseases, and
Externí odkaz:
https://doaj.org/article/6d73d621ce374d4eb5999ecb8e5d8476
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Tolvaptan-associated hepatic disorder is a rare, but lethal adverse event; however, the precise risk and time of onset remain unclear. This study aimed to characterize the severity, time‑to‑onset, and outcomes of hepatic disorder based o
Externí odkaz:
https://doaj.org/article/9e08396737fb4812ad71000cb8037e4b
Autor:
E. V. Shubnikova
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 3, Pp 309-330 (2024)
INTRODUCTION. Postmarketing surveillance is the main mechanism to monitor and evaluate the safety of drugs approved for widespread clinical use. This mechanism provides up-to-date information on adverse drug reactions and facilitates the implementati
Externí odkaz:
https://doaj.org/article/4627d7be30994585930da3fb93840522
Publikováno v:
Journal of Medicine and Life Science, Vol 21, Iss 3, Pp 83-91 (2024)
Adverse drug reactions (ADRs) are closely associated with increased morbidity and mortality rates, prolonged hospitalization durations, and higher healthcare costs. This study aimed to estimate the incidence, clinical features, and reporting status o
Externí odkaz:
https://doaj.org/article/1c2564fdf62e4915aa65780ccfb9a7d4
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug interactions associate
Externí odkaz:
https://doaj.org/article/5fe85e835f69445692ad453ca97b9064
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Publikováno v:
Vascular Health and Risk Management, Vol Volume 20, Pp 415-420 (2024)
Mariko Kozaru, Hiroko Kambara, Akari Higuchi, Tatsuki Kagatsume, Keiko Hosohata Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, 569-1094, JapanCorrespondence: Ke
Externí odkaz:
https://doaj.org/article/b61c939650e645acb2715f0d048cdeb7
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Trastuzumab emtansine (T-DM1) is widely utilized as a second-line and subsequent treatment for metastatic HER2+ breast cancer and has shown promise in early breast cancer treatment, particularly in adjuvant settings for residual disease afte
Externí odkaz:
https://doaj.org/article/cf8ea2b8612645708a91c061907a0d54